Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SillaJen Inc.

www.sillajen.com

Latest From SillaJen Inc.

Korean Biotech Sentiment Still Shaky But IPO Recovery Seen By Year-End

After a lackluster year so far for South Korean biotech IPOs amid disappointing clinical trial news, investor interest is beginning to pick up, with several companies that have been under the spotlight slated to debut on the market in the coming months.
South Korea Financing

Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics

South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.

South Korea Gene Therapy

Gene And Cell Therapies In Asia: New Korean Law To Change Landscape Of Cutting Edge Biologics

South Korea will undergo many changes as it gears up for a new law on cutting edge regenerative medicine and biologics, which will be implemented next year. Until then, further discussions will be needed to set details of the rules that can step up the industry’s competitiveness and bring the country more in line with global standards.

South Korea Gene Therapy

Genexine, ToolGen Merger Collapses Amid Stock Drops, But Collaboration Still Planned

The planned merger between Genexine and ToolGen, which was poised to create a major Korean biotech entity, has collapsed amid recent generally weak investor sentiment over the sector. But the two sides will maintain their collaborations for new drug development going forward, with a focus on gene and cell therapies.

South Korea M & A
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • SillaJen Co. Ltd.
  • SillaJen Biotherapeutics
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • SillaJen Inc.
  • Senior Management
  • Eun-Sang Moon, CEO
  • Contact Info
  • SillaJen Inc.
    Phone: 51 510 7550
    6F, 252, Geumjeong-ro
    Geumjeong-gu
    Busan, 46274
    South Korea
UsernamePublicRestriction

Register